Truist lowered the firm's price target on Vericel to $42 from $48 but keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in MedTech. The firm expects Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes, the analyst tells investors in a research note. Truist adds that the stock should be able to sustain a premium relative to its SMID peers given the company's above-20% growth prospects and emerging/accelerating profitability.
